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Rupley DM, Janda AM, Kapeles SR, Wilson TM, Berman D,
Mathur AK. Preconception counseling, fertility, and pregnancy
complications after abdominal organ transplantation: a survey and
cohort study of 532 recipients.
Abstract: Background: Pregnancy after solid organ transplant is a
signiﬁcant priority for transplant recipients but how patients report being
counseled is unknown.
Methods: We performed a single-center retrospective cohort study and
telephone survey of female patients ages 18–49 at the time of kidney,
pancreas, or liver transplant from 2000 to 2012 (n = 532). Data on
pregnancy counseling, fertility, and maternal, fetal- and transplant-
speciﬁc outcomes were collected. Multivariate Cox models assessed the
impact of pregnancy on graft-speciﬁc outcomes.
Results: The survey response rate was 29% (n = 152). One-third (n = 51)
of women were actively counseled against pregnancy by one or more
providers. A total of 17 pregnancies occurred among nine patients
(5.9%), with 47% live births, 47% early embryonic demises, 5.9%
stillbirths. Of live births, 50% were premature. Gestational
complications, including diabetes, hypertension, and preeclampsia were
present in 88% of mothers. Pregnancy after transplant was associated
with higher rates of acute rejection than nulliparous transplant recipients
(33% vs. 5.6%, p = 0.07) but did not signiﬁcantly aﬀect graft survival
(HR = 1.00, 95% CI 0.99–1.01), after stratifying by organ and adjusting
for clinical factors.
Conclusion: This study suggests that transplant patients are being
counseled against pregnancy despite acceptable risks of complications
and no speciﬁc eﬀects on long-term graft function.
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As the size of the reproductive-aged transplant
population continues to grow, expectations
regarding the feasibility, safety, and advisability
of pregnancy in solid organ recipients have chan-
ged substantially. Since 1958, over 14 000 births
have been reported worldwide in transplant recip-
ients of solid organs (1). Despite the increasing
prevalence of pregnancy in this population,
extensive gaps in understanding of the risks to
the graft, the organ recipient, and the fetus exist
among patients and their providers. These gaps
deter eﬀective counseling regarding fertility,
pregnancy, and the implications of these events
on graft function after solid organ transplant.
Currently, counseling patients about pregnancy
after transplant is hampered by the lack of high-
quality clinical data. Registries of pregnancy out-
comes in solid organ transplant recipients have
shown that pregnancy is feasible with a higher ges-
tational complication rate compared to normal
controls, and without a demonstrable eﬀect on
long-term graft function (1, 2). However, these data
are not systematically collected and are voluntarily
provided by patients and centers (3). These studies
have been criticized for inﬂating live birthrates
reported in the post-transplant population by
almost 10% over normal controls (4–7). Further
information regarding the consequences of
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© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Clin Transplant 2014: 28: 937–945 DOI: 10.1111/ctr.12393 Clinical Transplantation
immunosuppression on pregnancy outcomes are
also needed, but this fund of knowledge is limited
by small studies with heterogeneous drug regimens.
Although most pregnant solid organ recipients are
managed as high-risk obstetrical patients, standard
management procedures or protocols have yet to
be implemented for managing this population on a
wide scale. Although one study by McKay et al. in
2006 (8) was performed on patient counseling as
reported by providers, there are few data from
transplant patients regarding their counseling expe-
rience focusing on pregnancy following transplan-
tation. This study reported 82% of providers advise
against pregnancy following transplantation, with
30% of these providers basing their recommenda-
tion on institutional policies or protocols (8). The
lack of standardized and widely implemented rec-
ommendations for transplant patients regarding
pregnancy is a signiﬁcant problem that may aﬀect
clinical decision-making and quality of life. A better
understanding of how patients are counseled on
these risks during the transplant process is war-
ranted.
In this analysis, we conducted a telephone sur-
vey and retrospective cohort study on 532 female
solid organ transplant recipients at our center to
assess how patients have been counseled about fer-
tility and pregnancy, as well as determine predic-
tors of variation in maternal and fetal outcomes,
and delineate the eﬀect of pregnancy on transplant
outcomes.
Methods
Survey design and execution
The study was approved by the University of
Michigan Institutional Review Board. The study
population was derived as shown in Fig. 1. A
query was run through the Organ Transplant
Information System (OTIS), the medical records
system used at the University of Michigan for
every transplant patient, to obtain the contact
information for females who underwent solid
organ transplantation for a kidney, liver, or pan-
creas between the ages of 18–49 from 2000 to 2012
at the University of Michigan Health System.
Patients meeting survey criteria (n = 532) were
contacted via telephone and asked to voluntarily
participate in the 10–25 min survey (Appendix 1).
The surveys were conducted by trained personnel
under direction of the study authors and the
principal investigator (DR, AJ, AM). Interviewers
attempted to contact each patient on three separate
occasions. Patients were not included in further
analysis if contact was not established. Collected
data included information regarding patient demo-
graphics, socioeconomic status, clinical factors,
and graft outcomes. Subjects were not compen-
sated or rewarded for participation.
All collected information was de-identiﬁed and
stored on a secure server. These data were then ana-
lyzed in terms of counseling received, graft function
post-pregnancy, maternal gestational complications,
delivery complications, and neonatal outcomes.
Patients with prior history of permanent steriliza-
tion including previous hysterectomy, tubal ligation,
or Essure (Conceptus Inc, Mountain View, CA,
USA) were excluded. Data collection on prenatal
counseling included whether counseling against
pregnancy was given at the time of transplantation,
and which provider performed the counseling. Vari-
ables of interest to assess maternal outcomes
included: rate of conception, frequencies of live
birth, early embryonic loss, voluntary interruption
of pregnancy, stillbirth, and ectopic pregnancy.
Additionally, rates of gestational diabetes, gesta-
tional hypertension, preeclampsia, delivery compli-
cations, and frequency of breastfeeding were
recorded. Neonatal outcome variables included:
gestational age at delivery, birth weight, reported
neonatal complications, and ongoing childhood-
Number Called
N = 532
Not able to consent
N = 7
Able to consent
N = 407
Phone number no 
longer in operation
N = 117
Working phone 
number
N = 414
Able to reach
participant 
N=283
Not able to reach 
participant
N = 124
Agreed to participate
 N = 152
Declined the survey
N = 131
Met Criteria
N = 681
No phone number 
listed or  deceased
N = 149
Fig. 1. Calling tree ﬂow chart. Patients included in the study
are shown in solid boxes. A total of 152 patients participated
in the survey.
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chronic medical conditions. Transplant outcomes
related to graft function included: self-reported
acute rejection episodes, immunosuppressive medi-
cations, self-reported graft failure deﬁned as return
to dialysis or death for kidney transplant, re-trans-
plant or death for liver transplant, and documented
return to insulin usage for pancreas transplant. The
data obtained via the survey regarding graft out-
comes such as rejection episodes and graft failure
were veriﬁed with a query of OTIS and manual
chart review.
Retrospective cohort study design
To verify survey responses, chart reviews of the
study cohort were performed to gather speciﬁc
clinical data. Data obtained included immunosup-
pression regimen, incidence and type of graft-
speciﬁc complications, acute rejection, and graft
failure. Acute rejection was deﬁned as documented
histological evidence of rejection or a reported
increase in immunosuppression regimen due to
decreased graft function clinically, with subsequent
reversal of clinical dysfunction. Graft failure was
deﬁned as return to dialysis (renal failure), return
to insulin usage for pancreas transplants, need for
re-transplantation, or death.
Statistical design
Univariate statistics was performed to determine
clinical diﬀerences between survey respondents and
nonrespondents, and the eﬀect of pregnancy on
graft function. We subsequently used risk-adjusted
stratiﬁed multivariable Cox proportional-hazards
models with pregnancy as a time-varying covariate
to estimate its eﬀect of pregnancy on graft survival.
We used age, race, and clinical covariates collected
to risk adjust these estimates. The model structure
was stratiﬁed by organ type to optimize any esti-
mate of a pregnancy eﬀect on long-term graft func-
tion. All statistical analyses were conducted using
Stata 13 (College Station, TX, USA).
Results
Of the initial study cohort (n = 532), 283 subjects
were reached and 152 patients responded to the
survey (46% declined to participate). The overall
survey response rate was 29% (64% of reachable
subjects in the study cohort). Eighty-two percent
of respondents were kidney recipients, 19% were
liver recipients, and 13% were pancreas recipients
(Table 1). The demographics of the study
population are displayed in Table 1. There were no
signiﬁcant diﬀerences at the 95% level between
survey responders and non-responders for race,
age, type of organ transplanted, lifetime rejection,
or speciﬁc types of complications; however, there
were signiﬁcant diﬀerences between responders
and non-responders for lifetime graft loss and
lifetime complications with respondents being less
likely to have graft loss and more likely to have
complications (p = 0.037 and p = 0.036, respec-
tively).
Prenatal counseling
Fig. 2 illustrates survey responses regarding how
patients were counseled about pregnancy after
transplantation. One-third of survey respondents
(33.5%) were counseled against pregnancy by
one or more providers (including obstetricians,
hepatologists, nephrologists, and transplant
specialists) at any point in time. Forty-four
percent of all patients who became pregnant
were counseled against pregnancy at some point
after their transplantation, yet, still chose to
become pregnant.
Table 1. Frequency of demographics, graft complications, and
adverse outcomes for survey respondents and nonrespondents
Variable name
Survey
respondents (%) Nonrespondents (%)
n 152 529
Asian 5 (3.3)** 6 (1.1)**
Black 29 (19.1) 95 (18.0)
Hispanic 1 (0.7) 3 (0.6)
American Indian/
Alaska Native
0 (0)** 3 (0.6)**
Native Hawaiian/
Pacific Islander
0 (0)** 3 (0.4)**
White 113 (74.3) 379 (75.1)
Other 2 (2.6) 11 (2.1)
Age < 35 yr 68 (44.7)** 198 (37.4)**
Age > 35 yr 84 (55.3)** 331 (62.6)**
Type of organ
Kidney 125 (82.24) 422 (79.8)
Liver 29 (19.1) 107 (20.2)
Pancreas 20 (13.2) 58 (11.0)
Death 0 (0) 118 (22.3)
Lifetime rejection 11 (7.24%) 29 (5.5)
Lifetime graft loss 24 (15.8)* 187 (35.4)*
Lifetime complication 52 (34.2)* 133 (25.1)*
Type of complication
Infection 27 (17.8) 73 (13.8)
Reoperation 14 (9.2) 39 (7.4)
Acute post-op 13 (8.6) 46 (8.7)
Renal failure requiring
dialysis
9 (5.9)** 17 (3.2)**
Diabetes mellitus 6 (4.0) 13 (2.5)
Delayed graft function 2 (1.3)** 16 (3.0)**
*Statistically significant difference at the p < 0.05 level.
**Statistically significant difference at the p < 0.10 level.
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Pregnancy, delivery, and neonatal complications
Nine patients (5.9%) who responded to the sur-
vey were able to become pregnant, which resulted
in a total of 17 pregnancies because some sub-
jects had multiple pregnancies (Table 2). The 17
pregnancies resulted in eight live births (47%),
eight early embryonic demises (47%), and one
stillbirth (5.9%). Seven of 12 women actively
attempting conception were unsuccessful, result-
ing in a 58.3% infertility rate among our respon-
dents. Complications were present in 88% of
women with pregnancies resulting in a live birth,
including gestational diabetes, hypertension, and
preeclampsia, with 50% of subjects requiring
additional antenatal medical therapies including
antihypertensives to manage blood pressure and
diabetic medications to reduce hyperglycemia
(Table 3). Of the eight live births, 50% were born
prematurely, and with a median birth weight of
2.9 kg. Twelve percent of women reported neona-
tal complications including jaundice. Twenty-ﬁve
percent of children were diagnosed with chronic
medical complications, including asthma and
developmental delay.
Graft-related complications
Univariate analysis demonstrated women with
pregnancies post-transplantation trended toward
higher rates of acute rejection than nulliparous
recipients, although this diﬀerence was not statisti-
cally signiﬁcant (pregnant vs. nulliparous, 33% vs.
5.6%, p = 0.07). Furthermore, when parous vs.
nulliparous patients were stratiﬁed by organ
transplant type, there were no statistically signiﬁ-
cant diﬀerences in acute rejection (p = 0.12 for kid-
ney, p = 0.26 for liver, and too small of a sample
size for pancreas).
Graft survival for pregnant vs. nulliparous trans-
plant recipients was statistically diﬀerent at the
Fig. 2. Pregnancy counseling in kidney, liver, or pancreas recipients. Survey responses surrounding pregnancy counseling during the
transplant process and eventual pregnancy status after transplant. The majority of patients were not counseled against becoming
pregnant and never became pregnant, but a third of patients were advised to never become pregnant and never did.
Table 2. Demographics, graft complications, and adverse outcomes
for pregnant and nonpregnant survey respondents
Variable name
Pregnant
subjects (%)
Nonpregnant
subjects (%)
n 9 143
Asian 0 (0)* 5 (3.5)*
Black 1 (11.1) 28 (19.6)
Hispanic 0 (0) 1 (0.7)
White 8 (88.9) 105 (73.4)
Age < 35 yr 7 (77.8)* 61 (42.7)*
Age > 35 yr 2 (22.2)* 82 (57.3)*
Type of organ
Kidney 6 (66.7) 119 (83.2)
Liver 3 (33.3) 26 (18.8)
Pancreas 1 (11.1) 19 (13.3)
Pregnancy prior to Txp 0 (0) 87 (60.8)
Lifetime rejection 3 (33.3)** 8 (5.6)**
Lifetime graft loss 2 (22.2)* 22 (15.4)*
Lifetime complication 9 (100)* 43 (30.1)*
Type of complication
Infection 5 (55.6)* 22 (15.4)*
Reoperation 3 (33.3)** 11 (7.7)**
Acute post-op 5 (55.6)* 8 (5.6)*
Renal failure requiring dialysis 4 (44.4)* 5 (3.5)*
Diabetes mellitus 1 (11.1) 5 (3.5)
Delayed graft function 0 (0) 2 (1.4)
*Statistically significant difference at the p < 0.05 level.
**Statistically significant difference at the p < 0.10 level.
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95% level on univariate analysis; however, there
were no signiﬁcant diﬀerences in graft survival
when the population was stratiﬁed by each organ
subgroup. On multivariate analysis, pregnancy did
not have a signiﬁcant eﬀect on graft survival after
transplant (HR = 1.00, 95% CI 0.99–1.01) after
stratifying for organ type and adjusting for demo-
graphics and clinical covariates (Fig. 3).
Discussion
The clinical beneﬁt of abdominal organ transplan-
tation in managing end-organ failure in young
reproductive-aged women is undeniable. After
transplantation, renal and endocrine functions
rapidly return and fertility is often restored. Post-
transplant survival has reached an all-time high,
which has led to more focused attention on post-
transplant quality of life (9–11). Among the most
important of these concerns is the possibility of
regaining fertility, becoming pregnant, having chil-
dren, and the risks inherent to this pursuit for the
woman and the fetus. In this study, we conducted
a survey of female abdominal organ transplant
recipients from a large academic transplant center
to assess the nature of preconception counseling
focused on pregnancy, delivery, and maternal and
neonatal outcomes. We identiﬁed signiﬁcant varia-
tion in how patients were being counseled, and
observed cases of active dissuasion by transplant
providers, despite the increased but acceptable
risks and associated outcomes of pregnancy after
transplant. Our ﬁndings illustrate that signiﬁcant
gaps exist in improving prenatal counseling by
transplant and obstetric providers.
Although most pregnant solid organ recipients
are managed as high-risk obstetrical patients,
standard management procedures or protocols
have yet to be implemented for managing this
population on a wide scale. Despite consensus
from the American Society of Transplantation
that pregnancy is usually safe one yr post-trans-
plantation given that certain criteria are met,
most providers have continued to recommend
that patients wait two yr before becoming preg-
nant (1, 12). The factors to be achieved prior to
pregnancy include: stable allograft function with-
out episodes of rejection occurring in the past
year, stable immunosuppressive regimens consist-
ing of agents without known teratogenic risk,
and low-risk status for harmful opportunistic
infections (13, 14). Further studies are needed to
better characterize outcomes and risks of preg-
nancy in solid organ recipients. Studies
demonstrate that the majority of transplant pro-
viders currently advise women considering preg-T
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nancy based on “attending physician’s discretion”
as opposed to patient preference or protocols (8).
Standardized management practices would ideally
optimize outcomes for this unique population.
The principle aim of this analysis was to better
understand how transplant recipients are coun-
seled about the risks of pregnancy. In our study,
33.5% of respondents said they were advised
against pregnancy by at least one provider, which
included obstetricians, transplant surgeons,
hepatologists, and nephrologists. This is similar to
what is reported in a large Canadian study, and is
concerning in the context of relatively benign
risk-adjusted long-term graft outcomes (15).
Furthermore, among patients who successfully
conceived, 45% were advised against pregnancy.
This phenomenon calls for early counseling discus-
sions with transplant recipients of reproductive age
prior to conception to mitigate risks to both the
patient and oﬀspring in an eﬀort to remedy this
observed gap in provider understanding of the
risks and current guidelines. Eﬀorts to further edu-
cate providers on standard of care guidelines
should be initiated to disseminate knowledge more
broadly. Further study on factors associated with
delayed discussions of fertility and pregnancy with
patients should be undertaken (16).
The self-reported risk of complications in
pregnancy found in our analysis is consistent with
previous studies (17). Our data showed that the
rate of obstetric complications was signiﬁcantly
higher at 100% of our pregnant liver transplant
patients (n = 3), and at 88% of our entire study
cohort than the general population, consistent with
previous studies; previously reported rates of
obstetric complications in liver transplant
recipients were over 50% (4). The literature shows
that liver and kidney organ recipients have signiﬁ-
cantly higher rates of preeclampsia and gestational
diabetes in comparison with the general US popu-
lation (4, 5).
Furthermore, adverse delivery outcomes, includ-
ing preterm delivery and low birth weight, are also
well established in this population (18). The rate of
premature delivery in our study cohort (50% of
live births) was also signiﬁcantly higher than is
present in the general population (11%), according
to the Centers for Disease Control (13). The trans-
plant literature states that infants delivered to
female transplant recipients have a 50% likelihood
of being born premature, and nearly a 20% risk of
having intrauterine growth restriction (3, 19), well
above the 12.5% rate of prematurity and 5% risk
of intrauterine growth restriction in the general US
population (14, 20, 21). The high incidence of
prematurity has been associated with developmen-
tal delays, although this risk has not been well
characterized due to the limited longitudinal data
on oﬀspring outcomes (12). The implications of
these increased risks are clinically important to the
care and counseling of patients as they assess the
risks and beneﬁts of pregnancy after transplant.
These results support that transplant patients who
become pregnant need to be carefully monitored
throughout pregnancy, ideally with a high-risk
obstetrician, in an eﬀort to mitigate poor outcomes
from potential pregnancy complications (16).
These expanded eﬀorts and improved partnering
Fig. 3. Kaplan-Meier graft survival estimates of patients according to graft type and previous pregnancy status.
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between patients, obstetricians, and transplant
providers may improve maternal, fetal, and
neonatal outcomes in this growing at risk popula-
tion (16).
Unfortunately, we were unable to examine the
clinical outcomes of the children born from parents
with solid organ transplants. The reported inci-
dence of chronic medical conditions in these chil-
dren was interesting, but requires more detailed
analysis. Within the general population, the rate of
asthma is 9% (22) and developmental delay is
13.9% (23), which are similar to the rate found in
our study. Further research, from multiple centers,
may shed additional light on the speciﬁc risks to
the children of transplant recipients and aﬀect how
neonatal counseling should be directed for this
patient cohort.
Despite the poignant ﬁndings regarding how
transplant patients are counseled, our study had
numerous limitations. The survey design exposes
our conclusions to risks of recall bias. More com-
plete information on speciﬁc complications would
further sharpen our understanding of risks associ-
ated with pregnancy in this population. Addition-
ally, our study was limited by its observational
nature and cohort selection. Future studies should
examine outcomes in patients who underwent
transplantation prior to age of 18, a cohort which
was excluded and for whom risks associated with
pregnancy are especially relevant. Understanding
how women are counseled regarding the period of
time to avoid pregnancy post-transplantation
would be beneﬁcial. A follow-up study of provid-
ers’ counseling practices at this center might not
only illuminate the current practices of providers
and explain reasoning for recommendations
including clinical factors such as immunosuppres-
sive regimen and stability of graft but also could
shed light on the eﬀectiveness of providers’ discus-
sions with patients. Additionally, such a study
could demonstrate how provider practices have
changed since American Society of Transplant Sur-
geons (ASTS) pregnancy guidelines were released
in 2005. These details could guide creation of more
robust guidelines for transplant and obstetric
providers.
Pregnancy after transplant is an important clini-
cal issue that warrants further study to better
inform patients and providers about the risks and
optimal management considering this important
life decision. Educating physicians and patients
about the risks associated with pregnancy after
transplantation is crucial to improve patient care.
Further studies with pooled data from multiple
centers are warranted to better counsel patients
and providers.
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Appendix 1. Patient Phone Survey
Patient Phone Survey Study #______
1. Name:
2. Date of birth:
3. What is the location where your transplant was performed?_____________________
4. Where do you currently receive medical care regarding your transplant? ______________
5. Have you ever become pregnant prior to transplant? (Y/N)
6.1. Did you use any contraceptives following your transplant? (Y/N)
6.2. What type of contraceptive? (Abstinence, barrier, OCP/Nuvaring/patch, IUD, Implanon)
6.3. How long did you use contraceptives for?________ (months)
7. Did you have a hysterectomy, tubal ligation, or other permanent sterilization procedure prior to your transplant? (Y/N)
8. Did you develop diabetes requiring medication post-transplant prior to any pregnancy? (Y/N)
9. Did you develop hypertension or high blood pressure requiring medication post-transplant prior to any pregnancy? (Y/N)
10.1. Did you ever become pregnant after your transplant (repeat per pregnancy- record sequentially oldest to youngest)? (Y/N)
10.2. If so, how many pregnancies? _________ (number)
10.3. Was the pregnancy planned? (Y/N)
10.4. What was the length of the pregnancy? _______ (weeks)
10.5. What was the delivery/termination date? ___ /___/___ (date)
10.6. What hospital did you go to the for delivery/termination? (name, city, state) ________________
10.7. Did you have a miscarriage? (Y/N)
10.8. Did you have a termination? (Y/N)
10.9. Did you have any complications during your pregnancy? (Y/N)
10.10. Did you take any medication for hypertension or high blood pressure during your pregnancy? (Y/N)
10.11. Did you take any medication for diabetes during your pregnancy? (Y/N)
11. This section is regarding the outcome of any pregnancies you had.
11.1. What was the baby’s sex? (M/F)
11.2. What was the baby’s birth weight? _________(lbs, oz)
11.3. Was the baby healthy? (Y/N)
11.4. What was the baby’s Apgar scores? _______________(number, number, number)
11.5. Was the baby premature (Y/N)?
11.6. Did the baby have complications? (Y/N)
11.7. Was the baby stillborn? (Y/N)
11.8. How old is the child now? ________ (age in years)
11.9. Does the child have any chronic medical conditions? (Y/N)
11.10. What are they? (specify conditions)_________________
12.1. This section is on how your organ functioned before, during, and after pregnancy. Has your organ ever failed? (Y/N)
12.2. If so, when?___/___/____ (date)
12.3. Did your organ fail prior to pregnancy? (Y/N)
12.4. Did your organ fail during pregnancy? (Y/N)
12.5. Did your organ fail following delivery? (Y/N)
13. Immunosuppressant regimen at time of pregnancy:
13.1. Were you taking Neoral (cyclosporine capsules and oral solution)? (Y/N)
13.2. Were you taking Sandimmune (cyclosporine)? (Y/N)
13.3. Were you taking other cyclosporine formulations? (Y/N)
13.4. Were you taking Prograf (tacrolimus capsules and injection, or FJ506)? (Y/N)
13.5. Were you taking Cellcept (mycophenolate mofetil capsules)? (Y/N)
13.6. Were you taking Imuran (azathioprine)? (Y/N)
13.7. Were you taking Rapamune (sirolimus)? (Y/N)
13.8. Were you taking Myfortic (mycophenolic acid)? (Y/N)
13.9. Were you taking steroids (prednisone)? (Y/N)
13.10. Were you taking other immunosuppressants? (Y/N) (Specify)___________
13.11. Did you have any changes to immunosuppressant regimen during pregnancy? (Y/N)
(Specify)_________________________________________________________
14. Did you ever breastfeed following organ transplant? (Y/N)
14.1. For how long? __________(length in weeks)
14.2. What was your immunosuppressant regimen while breast feeding? (Specify)________________
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15. Were you actively trying to become pregnant since your transplant? ________________
16. Did any of your physicians tell you not to get pregnant? If so, which type of physician told you this?________________
Would you like to receive follow-up information regarding the results of the study?
If so, what is your address?
______________
______________
______________
This concludes the survey. Thank you for your time.
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